Triple-negative breast cancer (TNBC) lacks the expression of hormone receptors, and HER-2 is an aggressive tumor which is highly susceptible to metastasis, chemoresistance, and is insensitive to the classical anti-breast-cancer therapies and radiotherapy [179]. Here, ERBB2 is linked to breast carcinoma.